Back to News
Market Impact: 0.15
Sensorion Secures ANSM Approval To Launch Phase I/II HearConnex Trial Of SENS-601 In France
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany FundamentalsAnalyst Insights
Sensorion SA received ANSM authorization to begin HearConnex, a Phase I/II clinical trial of SENS-601. The approval is a modest positive clinical/regulatory milestone for the company, but no efficacy results or timelines for outcomes were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Paramount agrees invest $1.5 billion in domestic movies and create a board for editorial independence at CNN, CBS as part of deal for Warner Bros.
- Paramount and state AGs will settle lawsuit, allowing Warner Bros. merger to proceed, reports say
- Intel surges 12% as CPU stocks rally. Here's what's driving the move
- Paramount Set to Settle Lawsuits, Clearing Way for Warner Bros. Deal
- Paramount settles with US states in step towards merger with Warner Bros
- Paramount settles lawsuit blocking $110 billion Warner Bros. merger